Furthermore, high amounts of PD-L1 in NSCLC defined by these or other cut-off points may not accurately predict if anti-PD-1/PD-L1 therapy will successfully unleash a host anti-tumoral immune response. This evidence concerns the gene CD274 and non-small cell lung carcinoma.